AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 172 min read$RCKT

Shah Gaurav sold $10K of RCKT

Shah Gaurav (CEO) sold 2,837 shares of ROCKET PHARMACEUTICALS, INC. (RCKT) at $3.38 on 2026-08-13.

Original reporting
SEC EDGAR · Shah Gaurav
Published Aug 17, 2026, 9:52 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 17, 2026, 10:17 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$RCKT
Neutral
low confidence
Mentioned
$RCKT
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$RCKTNeutralLow
01

Why it matters

The CEO’s open-market sale reduces insider holdings and may slightly influence sentiment, but the disclosure lacks any accompanying operational or financial update.

02

Market read

A new insider-sale datapoint for RCKT, with limited trading implications absent other catalysts.

03

What to watch

Insider sales are common and frequently non-informational; traders should weigh this against any concurrent news (earnings, guidance, financing, clinical/regulatory updates) not present here.

Relevance 3/10Novelty 3/10Timing: filed after-hours on 2026-08-17, transaction dated 2026-08-13

Background

The article is a SEC Form 4 insider transaction disclosure for Rocket Pharmaceuticals, filed 2026-08-17.

Company-level read

Ticker impact

$RCKTNeutralLow confidence
Context

Rocket Pharmaceuticals CEO Shah Gaurav sold 2,837 shares in an open-market transaction at $3.3810/share, per a new Form 4 filing.

Expected impact

Likely limited near-term impact; any effect is sentiment-driven and typically fades unless paired with other news.

Evidence & confidence

The filing discloses transaction size, price, and post-sale holdings, but provides no new company performance, guidance, or regulatory/operational development.

Market effects

Sector

No clear sector read-through from a single small insider sale without accompanying company-specific developments.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

The absence of a disclosed 10b5-1 plan could be interpreted as less systematic selling, but insider sales still often reflect diversification or personal liquidity needs.

Key entities

  • issuer
    Rocket Pharmaceuticals, Inc.

    Company whose CEO insider sale is disclosed on Form 4.

  • insider
    Shah Gaurav

    CEO reporting an open-market sale of 2,837 shares.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

RCKT insider trading history →

Related articles

SEP 23
$RCKTHighAI 8/10

Rocket Pharmaceuticals (RCKT) Gets FDA Alignment on Heart Drug Trial. Can it Ease Safety Concerns?

Rocket Pharmaceuticals (RCKT) announced FDA agreement to include 3 patients in its Phase 2 trial for Danon disease gene therapy RP-A501, with 9 more to be enrolled. The modified protocol includes dose adjustments and enhanced safety monitoring. The FDA confirmed 12-month co-primary endpoints for efficacy. The trial aims to complete dosing by mid-2027, with primary assessment 12 months post-treatment. Safety and efficacy data remain key uncertainties.

insidermonkey.com2 min
SEP 17
$RCKTMed

Refinancing all but vanishes as mortgage rates climb

Major U.S. mortgage lenders adjusted their 30-year fixed rates following the Federal Reserve's rate hike. Rocket Mortgage and Bank of America increased rates, while U.S. Bank lowered its. Freddie Mac reported a national average rate of 6.76%, with refinance applications dropping 9% week-over-week. Home-equity products saw increased interest, and the NAHB/Wells Fargo Housing Market Index fell to 32 in September.

aol.com3 min
SEP 16
$UNPMed

This Union Pacific Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday - Ulta Beauty (NASDAQ:ULT

Analysts upgraded several companies: Needham upgraded Similarweb (SMWB) to Buy with a $11 target, Wolfe Research upgraded Paychex (PAYX) to Peer Perform, Needham upgraded Rocket Pharmaceuticals (RCKT) to Buy with a $9 target, UBS upgraded Union Pacific (UNP) to Buy with a $339 target, and Barclays upgraded Alvotech (ALVO) to Overweight with a $8 target.

benzinga.com2 min
SEP 16
$RCKTHighAI 8/10

Rocket Pharmaceuticals’ FDA Decision Clears ‘Meaningful Regulatory Overhang,’ Says Needham — Sees 150% Upside Potential In RCKT Stock

Rocket Pharmaceuticals (RCKT) received an FDA alignment on a pivotal study for its genetic disease therapy, leading to a 'Buy' upgrade from Needham with a $9 price target, implying 150% upside. The FDA confirmed continued enrollment in the Phase 2 study of RP-A501 for Danon Disease, with dosing expected to complete by mid-2027. The stock was up 7.6% on the news.

stocktwits.com2 min
SEP 16
$RCKTHighAI 8/10

Needham Upgrades Rocket Pharmaceuticals (RCKT) to Buy After FDA

Needham upgraded Rocket Pharmaceuticals (RCKT) to Buy with a $9 price target after FDA approved the trial design for RP-A501, a gene therapy for Danon Disease. The FDA's modifications include dosing and patient inclusion criteria. RCKT has no revenue, a $375M market cap, and a GF Score of 25, indicating financial stability but operational challenges. Insiders sold $1.0M in shares over the past year, while institutional guru ownership remains steady.

gurufocus.com2 min